Cat. No. 1213
Chemical Name: 2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
Biological ActivityInhibitor of mitogen-activated protein kinase kinase (MKK / MEK). Acts by binding to the inactivated form of MEK, thereby preventing its phosphorylation by cRAF or MEK kinase (IC50 = 2-7 μM). Inhibits cell growth and proliferation in acute myelogenous leukemia (AML) cell lines; causes G1 arrest by blocking p53-dependent p21 induction. Enhances embryonic stem cell self-renewal. Also available as part of the MAPK Cascade Inhibitor Tocriset™ and MAPK Inhibitor Tocriset™.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Alessi et al (1995) PD 98059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J.Biol.Chem. 270 27489. PMID: 7499206.
Dudley et al (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc.Natl.Acad.Sci.U.S.A. 92 7686. PMID: 7644477.
Tsang et al (1998) Effects of mitogen-activated protein kinase kinase inhibitor PD 98059 on antigen challenge of guinea-pig airways in vitro. Br.J.Pharmacol. 125 61. PMID: 9776345.
Qi et al (2004) BMP4 supports self-renewal of embryonic stem cells by inhibiting mitogen-activated protein kinase pathways. Proc.Natl.Acad.Sci.USA 101 6027. PMID: 15075392.
Kojima et al (2007) Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. 67 3210. PMID: 17409429.
If you know of a relevant citation for this product please let us know.
Keywords: PD 98059, supplier, Specific, inhibitors, MEK, MKK, Mitogen-Activated, Protein, Kinase, Kinases, PD98059, stem, cells
Find multiple products by catalog number
New Products in this Area
Potent MSK1 inhibitor; also inhibits other AGC group kinasesLH 846
Selective casein kinase 1δ inhibitorPPY A
Potent inhibitor of Abl T315l mutant and wild-type Abl kinasesFlavopiridol hydrochloride
Cyclin-dependent kinase inhibitorGSK2578215A
Potent, selective LRRK2 inhibitor; brain penetrantAmlexanox
Inhibitor of TBK1 and IKKε; antiallergic agentPF 05212384
Potent and selective dual PI 3-kinase/mTOR inhibitorPF 03814735
Aurora kinase A and B inhibitorPF 04691502
Dual PI 3-K/mTOR inhibitorTNP
Inhibitor of IP6K; also inhibits IP3KACHP
Selective IKKα and IKKβ inhibitorPD 0332991 isethionate
Potent, selective Cdk4/6 inhibitor; brain penetrantCZC 24832
Selective inhibitor of PI 3-Kinase γLY 333531 hydrochloride
Protein kinase C inhibitor; selective for β isozymesPF 06465469
Potent inhibitor of interleukin-2 inducible T cell kinase (ITK). Also inhibits BTK10Z-Hymenialdisine
Pan kinase inhibitor; potently inhibits MEK-1CP 690550 citrate
Potent JAK inhibitorWYE 687 dihydrochloride
Potent and selective mTOR inhibitor
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.